Board of Directors

Mike Sherman, Chairman

Mr. Sherman was named Chairman of the Board in August 2023. Prior to this role, Mr. Sherman was the Chief Executive Officer of Chimerix since 2019. Before joining the Company, he served as Chief Executive Officer of Endocyte and led it from a $200 million market capitalization to its $2.1 billion acquisition by Novartis in 2018. Mr. Sherman repositioned the company by re-prioritizing the pipeline, acquiring an external asset, and aggressively executing a phase 3 regulatory and clinical strategy. He joined the company in 2006 and as Chief Financial Officer and Chief Operating Officer and was instrumental in Endocyte’s IPO and four subsequent financings. Prior to joining Endocyte, Mr. Sherman served in various executive roles, including senor staff positions for the European and US operations of Guidant Corporation, a cardiovascular device manufacturer acquired by Boston Scientific Corporation. Mr. Sherman holds a BA in economics from DePauw University and an MBA from the Tuck School of Business at Dartmouth, graduating as a Tuck Scholar. Mr. Sherman currently serves on the Board of Directors at Werewolf Therapeutics, Inc. He also served on the Boards of Directors at Biospecifics Technologies, Inc. until the company’s acquisition by Endo Pharmaceuticals, Mead Johnson Nutrition until the company’s acquisition by Reckitt Benckiser and was the past Chairman of the Board of Trustees for the Children’s Museum of Indianapolis.

Martha J. Demski, Lead Independent Director

Ms. Demski has served on the Board of Directors since 2005 and was Chair from June 2018 thru July 2023. Ms. Demski also currently serves as a director of Alpha Teknova Inc. and Equillium Inc., both of which are public biopharmaceutical companies,. She chairs the audit committee and is a member of the compensation committee of both companies. She previously served as chair of the audit committee and compensation committee member of both Adamas Pharmaceuticals Inc. from 2014 to 2021 and ADMA Biologics Inc. from 2020 to 2023. Additionally, Ms. Demski has more than 13 years of banking experience with Bank of America.

Ms. Demski is a National Association of Corporate Directors Board Governance Fellow, and she received the Director of the Year in Corporate Governance award by the Corporate Directors Forum in 2017. Ms. Demski earned her BA from Michigan State University and an MBA from The University of Chicago Booth School of Business with concentrations in accounting and finance.

Mike Andriole

Mr. Andriole became President, CEO and a member of the Board of Directors of Chimerix in August 2023.

Prior to becoming President and CEO, Mr. Andriole was Chimerix’s Chief Business Officer and CFO from 2019 to 2023 during which time he led key strategic acquisitions, divestitures and capital raising transactions which reprioritized Chimerix’s pipeline and recapitalized the Company.

Prior to joining Chimerix, Mr. Andriole served as CFO of Endocyte, Inc., a leader in developing targeted treatments for prostate and other cancers, where he was instrumental in managing the company through a series of strategic transactions culminating in a sale to Novartis for $2.1 billion, including raising nearly $300 million in capital.

Prior to Endocyte, Mr. Andriole spent 16 years at Eli Lilly and Company in a range of financial, marketing and global business development roles.

Mr. Andriole earned a BSBA from Xavier University’s Williams School of Business and an MBA from Indiana University’s Kelley School of Business.

Lisa Decker, PhD

Lisa Decker, PhD, joined the Board of Directors for Chimerix in December 2023.  She currently serves as Chief Business Officer at IGM Biosciences, Inc and brings more than 25 years of drug development and business development experience.  Prior to her role at IGM Biosciences, Dr. Decker was Chief Business Officer at Atreca Inc., where she oversaw the business development and alliance management functions. Before that, she served in multiple roles at Nektar Therapeutics, most recently serving as Vice President, Business Development. Earlier in her career, Dr. Decker served in several roles at the Office of Technology Management at the University of Massachusetts Medical School. Dr. Decker received her PhD in Immunology from Tufts University School of Medicine.

Marc D. Kozin

Marc Kozin joined the Board of Directors for Chimerix in March 2024.  Mr. Kozin brings more than 35 years of experience in corporate and business strategy consulting, merger and acquisition advisory services, and value management. Mr. Kozin previously served as President of L.E.K., a global strategy consulting firm.  During his tenure at L.E.K., Mr. Kozin established the Boston office and led the development of the firm’s industry leading life science strategic planning practice. He advised senior executives in life sciences to help them identify new growth opportunities, build value, pursue highly-profitable mergers and acquisitions, and support sustained growth.   Mr. Kozin previously served on several Board of Directors  with successful exits, Endocyte to Novartis, Dyax to Shire, and Dicerna to Novo.  He currently serves on the Board of Directors of UFP Technologies (NASDAQ: UFPT) and HCRx Holdings.

In 2002, Consulting Magazine named Mr. Kozin one of the 25 most influential consultants in recognition of his leadership and results for clients. He holds a BS magna cum laude from Duke University, and an MBA with distinction from The Wharton School at the University of Pennsylvania.

Robert J. Meyer, MD

Dr. Meyer has served as one of our Directors since March 2018. He currently serves as Principal, Drug and Biological Products at Greenleaf Health, an FDA-focused strategic advising company. He is also an Associate Professor of Public Health Sciences at the University of Virginia, where he was formerly the Director of the Virginia Center for Translational and Regulatory Sciences from 2013-2017. Dr. Meyer previously was on the board of Cardiome Pharma and was a Trustee of the US Pharmacopeia for the 2015-2020 cycle. Prior to joining the faculty at UVA, Dr. Meyer was Vice President and Head, Global Regulatory Strategy, Policy and Safety at Merck Research Laboratories (MRL), joining Merck in October 2007. Prior to Merck, Dr. Meyer worked for the U.S. Food and Drug Administration (FDA) from 1994-2007. In his last five years at the FDA, Dr. Meyer was the Director for the Office of Drug Evaluation II (ODEII) within Center for Drug Evaluation and Research (CDER), with responsibilities for pulmonary and allergy, metabolic and endocrine, analgesics, anesthetics and rheumatologic drug products. Dr. Meyer holds a BA from Lehigh University and an MD from the University of Connecticut School of Medicine.

Fred A. Middleton

Mr. Middleton has served as one of our Directors since March 2018. He currently serves as a Managing Director of Sanderling Ventures, where he has worked for over 30 years as an investor, management team member and as a director in over 25 new biomedical ventures built in Sanderling’s venture investment portfolios since 1988. During his time at Sanderling, Mr. Middleton served as Vice Chairman and Chief Business Officer of Altor Biosciences, where he helped raise over $100M for clinical trials development and negotiated its subsequent acquisition by ImmunityBio, Inc. Mr. Middleton was an investor in Regeneron Pharmaceuticals and served as a board member and as the company’s CFO during its initial public offering in 1991. Earlier in his career, Mr. Middleton served as the third original member of the Genentech management team as its Chief Financial Officer from 1978-2004, completing its IPO in 1980. Mr. Middleton currently serves on the Boards of Directors for Calcimedica, Inc. (CALC) a publicly traded company and TheraVida, Inc. and Asteres, Inc, both privately held companies. Mr. Middleton holds a BS in Chemistry from the Massachusetts Institute of Technology and an MBA with Distinction from the Harvard Business School.

Pratik S. Multani, MD

Dr. Multani joined the Board of Directors for Chimerix in February 2020. He currently serves as Chief Medical Officer of ORIC Pharmaceuticals and brings more than 20 years of experience advancing oncology products from the clinic through regulatory approval. The other publicly company board on which Dr. Multani currently serves as a director is Erasca, Inc., a biotechnology company.  Prior to joining ORIC Pharmaceuticals, Dr. Multani served as Chief Medical Officer of Ignyta, which was acquired by Roche in 2017. Before joining Ignyta, Dr. Multani was Chief Medical Officer of Fate Therapeutics, and prior to that held multiple leadership positions at Kalypsys, Kanisa, and Salmedix. Dr. Multani started his biotech career at Biogen Idec., where he was involved with the development of both Zevalin and Rituxan for treatment of Non-Hodgkin Lymphoma. Earlier in his career, Dr. Multani held academic and clinical positions at Harvard Medical School and at Massachusetts General Hospital. His postdoctoral training included a fellowship in hematology and oncology at Dana-Farber Cancer Institute and an internship and residency in internal medicine at Massachusetts General Hospital. Dr. Multani received an MD from Harvard Medical School and an MS in clinical epidemiology from Harvard School of Public Health.

Vicki Vakiener

Ms. Vakiener joined the Board of Directors for Chimerix in April 2021. Over the course of her career, she has served as Epizyme’s Chief Commercial Officer where she led the company’s commercial efforts and oversaw the successful launch of Tazemetostat in two indications. For over 20 years, Vicki has held positions of leadership across Johnson & Johnson’s pharmaceuticals and diagnostics businesses focused in oncology. In addition, Vicki was the Vice President and Oncology Global Commercial Leader for Prostate Cancer at Janssen and led a cross-functional team to develop and execute the global commercial strategy for its portfolio of late stage and early pipeline compounds. She also previously served as the Vice President of Oncology Marketing at Janssen Oncology U.S., where she directed all marketing activities for ZYTIGA®, IMBRUVICA®, DARZALEX® and YONDELIS® and drove launch planning for ERLEADA® and ZEJULA®.

Vicki received a BS in Biochemistry from Albright College.